• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Heart Failure (HF) is a multi-faceted and life-threatening syndrome characterized by
significant morbidity and mortality, poor functional capacity and quality of life, and high costs …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with
reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30–40% of patients) …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibition reduces heart failure
hospitalizations in patients with diabetes, irrespective of glycaemic control. We examined the …

The prevalence of Type 2 diabetes mellitus (T2DM) has reached pandemic proportions.
T2DM frequently causes macrovascular and/or microvascular pathologic changes and …

Elevated levels of diastolic BP and especially systolic BP (SBP) are major risk factors for the
development of HF. 18, 19 One of the most impactful observations from the Framingham …

Epidemiologic and clinical data from the last 2 decades have shown that the prevalence of
heart failure in diabetes is very high, and the prognosis for patients with heart failure is …